CLL Society

Why do treatments for chronic lymphocytic #leukemia (#CLL) sometimes stop working? Learn more about BTK inhibitor resistance mutations in this activity, featuring an interview between Drs. Brian Koffman and Jennifer Woyach. Test your knowledge before and after watching the video to see how much you learned and print a handout with key takeaways. https://bit.ly/3AhITF1

Are you taking advantage of all CLL Society has to offer? Watch our video, Your CLL Journey Starts Here, to learn more about the wide range of programs and services we provide to support those living with CLL / SLL. Our goal is to empower every patient to receive the best care possible and enhance the quality of their life. https://lnkd.in/gmNYXBvE

Come get your CLL questions answered at CLL Society's "Ask Me Anything" Facebook live event on Nov. 15 at 9am PT / 12pm ET! CLL expert Dr. Alan Skarbnik from Novant Health will join to answer questions along with CLL patient advocate Michele Nadeem-Baker. This event is entirely dedicated to audience Q&A and you can join on Facebook or over Zoom. Learn more: https://bit.ly/3zWeU5y

This retroactive study aimed to understand why survival rates differ between Black and White patients with CLL/SLL. https://bit.ly/3UjpREY

If you missed the recent webinar with Dr. Michael Choi and patient advocate Larry Marion about managing side effects from CLL treatment, you can catch the replay, presentation slides, and transcript here! https://bit.ly/3XPM12V

For those living with #CLL, considering health factors beyond their diagnosis is essential. One factor researchers are looking to understand better is the impact of CLL/SLL on bone health and the risk of fractures. https://bit.ly/4eLBsoP

Frontline therapy selection for chronic lymphocytic leukemia (CLL) carries implications for sequential care, which increases the complexity of clinical decision-making in relapsed/refractory (R/R) disease. Join us on 10/24 at 7pm EDT for a virtual workshop hosted in collaboration with our partner PVI, PeerView Institute for Medical Education, which will pair mini lectures with case-based instruction and feature a panel of academic and community-based clinicians, will model the importance of collaborative decision-making for the optimal integration of non-covalent BTKi and CAR-T therapies for the treatment of R/R CLL. Register today to join in and build a resilient community of care! https://bit.ly/2024CLLL #MedEd

A triple combination treatment option of pirtobrutinib, venetoclax, and rituximab is being studied in a clinical trial for its efficacy against CLL/SLL. https://bit.ly/4837TMJ

Feeling overwhelmed by all of the practical and financial issues that come with a cancer diagnosis? Our partner Triage Cancer is hosting a FREE conference on October 25 & 26 for individuals diagnosed with cancer, care partners, and oncology health care professionals: https://bit.ly/3wWMwOG #TriageTalks #CancerRights #beyonddiagnosis #cancerisntfree #cancerfinances #workandcancer

Individuals living with CLL/SLL have an impaired immune system, which means they have a harder time fighting off infections. Dr. Piers Patten explains the importance of immune considerations for these people. https://bit.ly/4eAObup